JP4588447B2 - 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 - Google Patents

過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 Download PDF

Info

Publication number
JP4588447B2
JP4588447B2 JP2004527956A JP2004527956A JP4588447B2 JP 4588447 B2 JP4588447 B2 JP 4588447B2 JP 2004527956 A JP2004527956 A JP 2004527956A JP 2004527956 A JP2004527956 A JP 2004527956A JP 4588447 B2 JP4588447 B2 JP 4588447B2
Authority
JP
Japan
Prior art keywords
seq
sequence
fusion
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004527956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515983A (ja
JP2006515983A5 (enExample
Inventor
ロジャー ブリースウィッツ，
ジョン エイチ． グリフィン，
Original Assignee
セラヴァンス， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス， インコーポレーテッド filed Critical セラヴァンス， インコーポレーテッド
Publication of JP2006515983A publication Critical patent/JP2006515983A/ja
Publication of JP2006515983A5 publication Critical patent/JP2006515983A5/ja
Application granted granted Critical
Publication of JP4588447B2 publication Critical patent/JP4588447B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004527956A 2002-08-09 2003-08-08 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 Expired - Fee Related JP4588447B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40233002P 2002-08-09 2002-08-09
US44049103P 2003-01-16 2003-01-16
PCT/US2003/024992 WO2004015082A2 (en) 2002-08-09 2003-08-08 Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010166564A Division JP2010279376A (ja) 2002-08-09 2010-07-23 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法

Publications (3)

Publication Number Publication Date
JP2006515983A JP2006515983A (ja) 2006-06-15
JP2006515983A5 JP2006515983A5 (enExample) 2010-09-16
JP4588447B2 true JP4588447B2 (ja) 2010-12-01

Family

ID=31720590

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004527956A Expired - Fee Related JP4588447B2 (ja) 2002-08-09 2003-08-08 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
JP2010166564A Ceased JP2010279376A (ja) 2002-08-09 2010-07-23 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010166564A Ceased JP2010279376A (ja) 2002-08-09 2010-07-23 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法

Country Status (5)

Country Link
US (4) US7195876B2 (enExample)
EP (1) EP1576129A4 (enExample)
JP (2) JP4588447B2 (enExample)
AU (1) AU2003259713A1 (enExample)
WO (1) WO2004015082A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162203A0 (en) * 2001-12-27 2005-11-20 Theravance Inc Indolinone derivatives useful as protein inase inhibitors
CA2488876A1 (en) 2002-06-13 2003-12-24 Oregon Health & Science University Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
JP4776537B2 (ja) 2003-05-27 2011-09-21 ロベルト・ペール・ヘーガークヴィスト 糖尿病処置のためのチロシンキナーゼ阻害剤の使用
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
JP2009528365A (ja) * 2006-02-28 2009-08-06 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04505260A (ja) * 1989-05-22 1992-09-17 ザイモジェネティクス，インコーポレイティド ＰＤＧＦα―受容体
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1192250A2 (en) * 1999-06-17 2002-04-03 Incyte Genomics, Inc. Human rna metabolism proteins (rmep)
PT1255752E (pt) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
JP5073147B2 (ja) 2000-08-18 2012-11-14 ミレニアム ファーマシューティカルズ インク． キナーゼインヒビターとしてのキナゾリン誘導体
IL162203A0 (en) * 2001-12-27 2005-11-20 Theravance Inc Indolinone derivatives useful as protein inase inhibitors
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same

Also Published As

Publication number Publication date
US7585653B2 (en) 2009-09-08
EP1576129A2 (en) 2005-09-21
JP2006515983A (ja) 2006-06-15
US20100112661A1 (en) 2010-05-06
JP2010279376A (ja) 2010-12-16
US20080102472A1 (en) 2008-05-01
AU2003259713A1 (en) 2004-02-25
US20090087881A1 (en) 2009-04-02
WO2004015082A3 (en) 2007-04-26
WO2004015082A2 (en) 2004-02-19
EP1576129A4 (en) 2008-01-23
AU2003259713A8 (en) 2004-02-25
US7604944B2 (en) 2009-10-20
US20040045044A1 (en) 2004-03-04
US7195876B2 (en) 2007-03-27

Similar Documents

Publication Publication Date Title
US7964710B2 (en) EML4-ALK fusion gene
JP5562640B2 (ja) ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
JP6259320B2 (ja) ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
JP6144247B2 (ja) ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
JP2010279376A (ja) 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
US20100143918A1 (en) Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20050265987A1 (en) Sulfatases and methods of use thereof
US8404810B2 (en) Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
US20100266580A1 (en) Translocation and mutant tnk1 kinase in human lymphoma
JP6740172B2 (ja) ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
JP6141224B2 (ja) ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
JP2020156481A (ja) ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
Cohen et al. Etk
US20090197269A1 (en) Translocation and mutant CSF1R Kinase in human leukemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100325

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100723

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100823

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100908

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130917

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees